The Value of Genetics in Stroke Management — by BValue
Home News The Value of Genetics in Stroke Management — by BValue

The Value of Genetics in Stroke Management — by BValue

OCTOBER 22, 2025 Members' News

The Value of Genetics in Stroke Management — by BValue

BValue Successfully Launched the Official Genetic Test – Genedrive® CYP2C19 During the World Stroke Congress

BValue is proud to announce the official launch of Genedrive® CYP2C19, the first and only point-of-care (POC) genetic test for stroke patients in Spain. The launch took place from October 22nd to 24th during the prestigious World Stroke Congress.

The Genedrive CYP2C19 test leverages rapid PCR technology to deliver 99.9% reliable results in under 69 minutes — directly at the point of care. It enables immediate identification of patients who are non-metabolisers of Clopidogrel, a genetic variant found in up to 30% of the European population. These patients face a significantly higher risk of recurrent cerebrovascular events if standard therapy is used.

With this solution, clinicians can now personalise antiplatelet therapy within the first 24 hours after a stroke or TIA, in line with the NICE Guidelines (UK), which recommend Genedrive CYP2C19 testing when laboratory results are not available in time.

Clopidogrel remains the most prescribed antiplatelet therapy, yet genetic resistance can render it ineffective in a large subset of patients. Dual antiplatelet therapy (DAPT) — typically combining aspirin with Clopidogrel or Ticagrelor — is recommended by both U.S. and EU Guidelines to be initiated within 12–24 hours following a minor stroke or high-risk TIA. However, conventional lab testing often fails to provide actionable results within this critical window.

By introducing a validated, bedside genotyping tool, BValue empowers stroke teams to make faster, more precise treatment decisions — helping to reduce the risk of recurrent events by up to 30%, as supported by evaluations from NICE in the UK.

With this launch, BValue reinforces its commitment to value-based healthcare, enabling better clinical outcomes, more efficient use of public resources, and wider access to precision medicine in the management of Stroke and TIA. 

November 20, 2026 Members' News
Derm2check Breaks Away From One-Sided AI Skin Apps
Dutch platform combines a free AI skin check with an international network of dermatologists, from first suspicion to treatment Derm2check is the result of a pilot phase of about a year, during which broad experience was built up worldwide in digital dermatological care. That practical experience has now been incorporated into a fully renewed platform, which combines AI technology with a free AI Check for users.
Read more
November 20, 2026 Members' News
SMED Clinical Research joins the Barcelona & Madrid Health Hub
Joining Barcelona & Madrid Health Hub marks an important step for SMED Clinical Research as the company continues to strengthen its presence within the healthcare and life sciences ecosystem. It creates new opportunities to stay close to innovation, collaborate with leading organisations, and better understand the evolving needs of sponsors, clinical sites and the patients they serve.
Read more
November 19, 2026 Members' News
Partner Insights 2026: Technology, Innovation and Collaboration in Life Sciences
Ambit Iberia has launched Partner Insights 2026, the new edition of its annual magazine bringing together the perspectives of 13 technology partners on the trends, challenges and opportunities shaping the future of the Life Sciences industry.
Read more
November 19, 2026 Members' News
Artificial Intelligence comes to informed consent to answer patients’ questions before surgery
Informed consent is a routine process in any hospital, but its management continues to generate costs, administrative workload and traceability issues when carried out on paper. To address these challenges, ASHO has developed a new end-to-end informed consent management platform that digitizes the entire process and gives patients a more active role, allowing them to access the information in advance, resolve their questions before signing and arrive at surgery with a better understanding of the procedure.
Read more
November 18, 2026 Members' News
Corporate Nutrition for Every Type of Work. The Great Blind Spot in Workplace Wellness
Do we really take care of all the factors that influence team well-being? In recent years, companies have made progress in mental health, work-life balance, flexibility, and creating healthier work environments. However, there is one element that often remains outside the strategy or is treated in a merely informative way: nutrition during the workday.
Read more
November 17, 2026 Events of the ecosystem
Madrid Health Hub leads the conversation at Horizon Deep Tech Summit
On November 12th, Madrid Health Hub brought together experts from Eurecat, Bitsphi and Clave Capital at Horizon Deep Tech Summit 2026 to explore how healthcare ecosystems can accelerate innovation.  
Read more
November 16, 2026 Members' News
M2H brings exercise prescription into Primary Care: doctors and exercise specialists, finally on a single digital layer
The Barcelona-based healthtech startup, a new member of Barcelona & Madrid Health Hub, connects family doctors and Physical Exercise Specialists within the same clinical workflow, keeping full patient traceability.
Read more
November 13, 2026 Members' News
The Ultimate Guide for Choosing an Enterprise CMS
In strictly regulated industries like pharmaceutical and health insurance, delivering seamless, compliant digital experiences—from patient portals to provider resources—is critical. Magnolia is a leading composable Digital Experience Platform (DXP) trusted by healthcare and global enterprise giants like Sanofi and Generali. By centralizing websites, portals, and apps into one intuitive, open platform, Magnolia's CMS empowers IT teams to build freely and marketing teams to launch faster—all while protecting brand integrity and compliance.
Read more
November 13, 2026 Members' News
Fund It, Build It, Certify It: A MedTech Startup's Roadmap to Market
Most MedTech startups don't stall because the technology fails. They stall because funding and regulation were planned separately. Under MDR, compliance is not the last step before submission. It shapes your product and company decisions from day one. And investors know it: before a Series A or B, they expect a credible regulatory strategy, not just a promising prototype. That's why, QbD Group and Capital Cell teamed up, to bring both sides together in one free webinar live session.
Read more
November 12, 2026 Members' News
Health Tech Enterprise launches half-price UK market entry offer for Barcelona & Madrid Health Hub members
Health Tech Enterprise introduces an exclusive UK Market Entry Pathfinder offer for Barcelona & Madrid Health Hub members, helping MedTech companies assess their readiness for UK expansion and receive an evidence-based market entry recommendation within 21 days, with preferential member pricing available until 31 December 2026.
Read more